Targeting RNA modifications to change breast cancer behavior
Official title: Disrupting long noncoding RNA methylation to elicit antimorph behavior in breast cancer
Funded at University of Colorado Denver · NIH-10818526 · Data updated 2026-11-12
This study is looking at how changing certain tiny parts of RNA in breast cancer can help turn them from promoting cancer to fighting it, which could lead to new treatments that help patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | May 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $207,185 |
| NIH project number | 5R21CA270573-02 |
| Project ID | NIH-10818526 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with breast cancer, particularly those with specific LncRNA profiles.
✕Less likely to help
Patients with non-breast cancer malignancies or those whose cancer does not involve the targeted LncRNAs may not benefit from this research.
What this research studies
This research investigates how specific long noncoding RNAs (LncRNAs) in breast cancer can be modified to switch their role from promoting cancer to suppressing it. By focusing on a single nucleotide mutation that prevents RNA methylation, the study aims to enhance the expression of a converted LncRNA that can reduce cancer characteristics more effectively than simply removing the cancer-promoting RNA. The researchers will explore this novel therapeutic approach to disrupt the m6A methylation pathway, potentially leading to new treatments for breast cancer. Patients may benefit from insights that could translate into innovative therapies targeting these RNA modifications.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively reduce breast cancer progression by modifying RNA behavior.
How similar studies have gone: While the approach of targeting RNA modifications is relatively novel, preliminary findings suggest that similar strategies have shown promise in other cancer types.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Johnson, Aaron M. — University of Colorado Denver
- Study coordinator: Johnson, Aaron M.
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.